Kyle Bass' Hayman Capital has traded in its oil stocks for pharma one, among other things.
Hayman's top holding is still NMI Holdings (NMIH) - now 26% of the long portfolio. They added an Impax Labs (IPXL) stake which is the 3rd largest holding and a CF Industries (CF) stake - 4th largest. As well, the GW Pharma (GWPH) stake is new - 5th largest. It upped its BioMarin Pharma (BMRN) and Vertex Pharma (VRTX) stakes by more than tenfold to make them its 6th and 7th largest positions.
RECAP: Lost of new pharma stakes and increases, while dumping oil.
New notables - IPXL, CF, GWPH, DBVT, DNAI, ERES, AGN ADHD - all to hedge out his short positions (jihad) on other pharma companies.
Notable selloffs - Perrigo (PRGO) - sold all and was its 2nd largest holding, Mylan (MYL) sold 89% and was 3rd largest; sold all OAS, WLL, NFX, SM, CJES, PDCE, FANG, MTDR, BCEI, CXO, RES, etc.
Hayman's portfolio went from 44% energy and 26% healthcare to now 16% energy and 45% healthcare.
Don't forget - sign up for our free daily newsletter to stay in the activist investing know.